PKUK Technical Meeting

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce its attendance at the upcoming PKUK Technical Meeting. This event, which brings together experts across the PKPD and quantitative pharmacology field, will take place on 27-29 November 2024 at Coppid Beech Hotel, Bracknell, UK and serves as a platform to explore PKPD-related topics, including research, development, application, methodologies, and practical usage. 

 

Representing Physiomics at the event will be Dr Mark Davies, Head of Quantitative Pharmacology and Data Science, and Dr Lea Sta, BioSimulation Scientist. Mark and Lea will engage with fellow scientists and industry professionals to discuss the latest advancements in pharmacokinetics and the transformative applications of modelling and simulation across the drug development process. 

 

PKUK has a long history of fostering collaboration and innovation in pharmacokinetics, with its technical meetings serving as a valuable forum for exchanging ideas and advancing understanding in this critical area. Physiomics looks forward to contributing to these discussions and exploring new ways to integrate state-of-the-art modelling and simulation into the broader context of drug development. 

 

To view the PKUK full programme see here and for more information about Physiomics please visit www.physiomics.co.uk. 

 

 

Enquiries: 

 

Physiomics plc 

Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980 

  

Hybridan LLP (Broker) 

Claire Louise Noyce 

+44 (0) 203 764 2341 

  

Strand Hanson Ltd (NOMAD) 

James Dance & James Bellman 

+44 (0)20 7409 3494 

   

  

Notes to Editor 

   

About Physiomics 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies. 

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.